GlaxoSmithKline plc, and its subsidiary and associated undertakings, constitute a major global healthcare group engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline has its corporate head office in the London area at:

Glaxo Wellcome House
Berkeley Avenue
Greenford
Middlesex UB6 0NN
England
Tel: 020 8966 8000

GlaxoSmithKline has an operational headquarters in Philadelphia, USA, and operating companies in some 70 countries, with products sold in over 140 countries. The principal research and development (R&D) facilities are in the UK, USA, Japan, Italy and Belgium and products are currently manufactured in some 41 countries.

The major markets for the Group’s products are the USA, Japan, the UK, France, Germany and Italy.

GlaxoSmithKline plc is a public limited company incorporated on 6th December 1999 under English law. On 27th December 2000 the company acquired Glaxo Wellcome plc and SmithKline Beecham plc, both English public limited companies, by way of a scheme of arrangement for the merger of the two companies. Both Glaxo Wellcome and SmithKline Beecham were major global healthcare businesses.


Business segments
GlaxoSmithKline operates principally in two industry segments:

• Pharmaceuticals (prescription pharmaceuticals and vaccines)
• Consumer Healthcare (over-the-counter medicines, oral care and nutritional healthcare).

The businesses in the Healthcare Services segment (primarily Clinical Laboratories and Diversified Pharmaceutical Services) were disposed of in 1999.